NASDAQ:PRPO - Precipio Stock Price, Forecast & News

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Shares of Precipio reverse split on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

Precipio (NASDAQ:PRPO) posted its earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative net margin of 525.32% and a negative return on equity of 94.75%. View Precipio's Earnings History.

Precipio is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Precipio.

1 equities research analysts have issued 1-year target prices for Precipio's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Precipio's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 141.0% from the stock's current price. View Analyst Price Targets for Precipio.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Precipio.

News coverage about PRPO stock has trended very negative on Sunday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precipio earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Precipio.

Some companies that are related to Precipio include HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), Inpixon (INPX), Jaguar Health (JAGX), MannKind (MNKD), AEterna Zentaris (AEZS), Cellectar Biosciences (CLRB), Inovio Pharmaceuticals (INO), MEI Pharma (MEIP) and TrovaGene (TROV).

Precipio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Spark Investment Management LLC (0.42%). Company insiders that own Precipio stock include Ilan Danieli and Randal J Kirk. View Institutional Ownership Trends for Precipio.

PRPO stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Precipio.

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRPO stock can currently be purchased for approximately $1.66.

Precipio has a market capitalization of $13.31 million and generates $2.86 million in revenue each year. Precipio employs 42 workers across the globe.View Additional Information About Precipio.

The official website for Precipio is http://www.precipiodx.com/.

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]